Cargando…
Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
BACKGROUND: Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, treatment has not been uniform throughout the published literature. CASES: We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently trea...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161682/ https://www.ncbi.nlm.nih.gov/pubmed/21892277 |
_version_ | 1782210722149695488 |
---|---|
author | Janszen, Erica W.M. van Doorn, Helena C. Ewing, Patricia C. de Krijger, Ronald R. de Wilt, Johannes H.W. Kam, Boen L.R. de Herder, Wouter W. |
author_facet | Janszen, Erica W.M. van Doorn, Helena C. Ewing, Patricia C. de Krijger, Ronald R. de Wilt, Johannes H.W. Kam, Boen L.R. de Herder, Wouter W. |
author_sort | Janszen, Erica W.M. |
collection | PubMed |
description | BACKGROUND: Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, treatment has not been uniform throughout the published literature. CASES: We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently treated with thyroidectomy and (131)I ablation therapy, two patients as first line management, one following the occurrence of metastatic disease. CONCLUSION: Histological diagnosis of malignant struma ovarii is similar to that of well differentiated thyroid carcinoma (WDTC). In line with the latest advice on treatment of WDTC, we believe that the best option for patients with malignant struma ovarii is surgical removal of the ovarian lesion followed by total thyroidectomy which allows the exclusion of primary thyroid carcinoma, and in addition, allows radioiodine ((131)I) ablation therapy for (micro) metastasis. After thyroidectomy, thyroglobulin can be used as a tumor marker for follow-up. Moreover, nuclear medicine imaging using radioiodine ((123)I) can be performed to demonstrate metastatic carcinoma. A multidisciplinary approach is essential. |
format | Online Article Text |
id | pubmed-3161682 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-31616822011-09-02 Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy Janszen, Erica W.M. van Doorn, Helena C. Ewing, Patricia C. de Krijger, Ronald R. de Wilt, Johannes H.W. Kam, Boen L.R. de Herder, Wouter W. Clin Med Oncol Case Report BACKGROUND: Malignant struma ovarii is a rare malignant germ cell tumor of the ovary. Due to the rarity of this disease, treatment has not been uniform throughout the published literature. CASES: We present three cases of malignant struma ovarii. Following primary surgery, all were subsequently treated with thyroidectomy and (131)I ablation therapy, two patients as first line management, one following the occurrence of metastatic disease. CONCLUSION: Histological diagnosis of malignant struma ovarii is similar to that of well differentiated thyroid carcinoma (WDTC). In line with the latest advice on treatment of WDTC, we believe that the best option for patients with malignant struma ovarii is surgical removal of the ovarian lesion followed by total thyroidectomy which allows the exclusion of primary thyroid carcinoma, and in addition, allows radioiodine ((131)I) ablation therapy for (micro) metastasis. After thyroidectomy, thyroglobulin can be used as a tumor marker for follow-up. Moreover, nuclear medicine imaging using radioiodine ((123)I) can be performed to demonstrate metastatic carcinoma. A multidisciplinary approach is essential. Libertas Academica 2008-02-29 /pmc/articles/PMC3161682/ /pubmed/21892277 Text en © 2008 the author(s), publisher and licensee Libertas Academica Ltd. http://creativecommons.org/licenses/by/3.0 This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Case Report Janszen, Erica W.M. van Doorn, Helena C. Ewing, Patricia C. de Krijger, Ronald R. de Wilt, Johannes H.W. Kam, Boen L.R. de Herder, Wouter W. Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy |
title | Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy |
title_full | Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy |
title_fullStr | Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy |
title_full_unstemmed | Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy |
title_short | Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy |
title_sort | malignant struma ovarii: good response after thyroidectomy and (131)i ablation therapy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161682/ https://www.ncbi.nlm.nih.gov/pubmed/21892277 |
work_keys_str_mv | AT janszenericawm malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy AT vandoornhelenac malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy AT ewingpatriciac malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy AT dekrijgerronaldr malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy AT dewiltjohanneshw malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy AT kamboenlr malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy AT deherderwouterw malignantstrumaovariigoodresponseafterthyroidectomyand131iablationtherapy |